Experimental lymphoma drug CPO107 tested in small early trial
NCT ID NCT04853329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited information about whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPO107 (a bispecific fusion protein targeting CD20 and CD47)
What this could lead to
If successful, this could point toward a new treatment option for patients with advanced Non-Hodgkin lymphoma who have run out of standard therapies.
What could go wrong
This was a very early (Phase 1), small trial (only 7 participants) that was terminated early, so results are limited. It is unclear if CPO107 is safe or effective, and it may not work in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novant Health
Charlotte, North Carolina, 28204, United States